Abstract：
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with synovial proliferation and bone erosion, which leads to the structural and functional impairment of the joints. Immune cells, together with synoviocytes, induce a pro-inflammatory environment and novel treatment agents target inflammatory cytokines. Psoriasis is a chronic immune-mediated skin disease, and several cytokines are considered as typical mediators in the progression of the disease, including IL-23, IL-22, and IL-17, among others.
In this review, we try to evaluate whether cyclin-dependent kinases (CDK), enzymes that regulate cell cycle and transcription of various genes, could become novel therapeutic targets in RA and psoriasis. We present the main results of in vitro and in vivo studies, as well as scarce clinical reports.
CDK inhibitors seem promising for treating RA and psoriasis because of their multidirectional effects. CDK inhibitors may affect not only the process of osteoclastogenesis, thereby reducing joint destruction in RA, but also the process of apoptosis of neutrophils and macrophages responsible for the development of inflammation in both RA and psoriasis. However, assessing the efficacy of these drugs in clinical practice requires multi-center, long-term clinical trials evaluating the effectiveness and safety of CDK-blocking therapy in RA and psoriasis.
In this review, we try to evaluate whether cyclin-dependent kinases (CDK), enzymes that regulate cell cycle and transcription of various genes, could become novel therapeutic targets in RA and psoriasis. We present the main results of in vitro and in vivo studies, as well as scarce clinical reports.
CDK inhibitors seem promising for treating RA and psoriasis because of their multidirectional effects. CDK inhibitors may affect not only the process of osteoclastogenesis, thereby reducing joint destruction in RA, but also the process of apoptosis of neutrophils and macrophages responsible for the development of inflammation in both RA and psoriasis. However, assessing the efficacy of these drugs in clinical practice requires multi-center, long-term clinical trials evaluating the effectiveness and safety of CDK-blocking therapy in RA and psoriasis.
摘要：
类风湿性关节炎（RA）是一种与滑膜增生和骨侵蚀相关的慢性炎症性疾病，这导致关节的结构和功能受损。免疫细胞,连同滑膜细胞，诱导促炎环境和新的治疗剂靶向炎性细胞因子。银屑病是一种慢性免疫介导的皮肤病,几种细胞因子被认为是疾病进展的典型介质，包括IL-23、IL-22和IL-17等。
■在这篇评论中，我们试图评估细胞周期蛋白依赖性激酶(CDK)调节细胞周期和各种基因转录的酶，可能成为RA和银屑病的新治疗靶点。我们介绍了体外和体内研究的主要结果，以及稀缺的临床报告。
■CDK抑制剂由于其多向作用，似乎有望用于治疗RA和银屑病。CDK抑制剂可能不仅影响破骨细胞生成的过程，从而减少RA中的关节破坏，而且是中性粒细胞和巨噬细胞凋亡的过程，负责RA和牛皮癣的炎症发展。然而,评估这些药物在临床实践中的疗效需要多中心，评估CDK阻断疗法在RA和银屑病中的有效性和安全性的长期临床试验。
■在这篇评论中，我们试图评估细胞周期蛋白依赖性激酶(CDK)调节细胞周期和各种基因转录的酶，可能成为RA和银屑病的新治疗靶点。我们介绍了体外和体内研究的主要结果，以及稀缺的临床报告。
■CDK抑制剂由于其多向作用，似乎有望用于治疗RA和银屑病。CDK抑制剂可能不仅影响破骨细胞生成的过程，从而减少RA中的关节破坏，而且是中性粒细胞和巨噬细胞凋亡的过程，负责RA和牛皮癣的炎症发展。然而,评估这些药物在临床实践中的疗效需要多中心，评估CDK阻断疗法在RA和银屑病中的有效性和安全性的长期临床试验。
